To Explore the Mechanism of Maiwei Dihuang Decoction in the Treatment of Non-small Cell Lung Cancer based on Network Pharmacology Combined with LC-MS


Cite item

Full Text

Abstract

Objective:To explore the mechanism of Maiwei Dihuang decoction in the treatment of non-small cell lung cancer (NSCLC) by using network pharmacology and LC-MS technology.

Methods:The effective components in Maiwei Dihuang decoction were detected by liquid chromatography- mass spectrometry (LC-MS). Use the SuperPred database to collect the relevant targets of the active ingredients of Mai Wei Di Tang, and then collect the relevant targets of nonsmall cell lung cancer from GeneCards, DisgenNET and OMIM databases. On this basis, PPI network construction, GO enrichment analysis and KEGG pathway annotation analysis were carried out for target sites. Finally, AutoDock Vina is used for molecular docking.

Results:We further screened 16 effective Chinese herbal compounds through LC-MS combined with ADME level. On this basis, we obtained 77 core targets through protein interaction network analysis. Through GO, KEGG analysis and molecular docking results, we finally screened out the potential targets of Maiwei Dihuang Decoction for NSCLC: TP53, STAT3, MAPK3.

Conclusion:Maiwei Dihuang decoction may play a role in the treatment of NSCLC by coregulating TP53/STAT3/MAPK3 signal pathway.

About the authors

Tao Jiang

Department of Pharmacy, Navy Anqing Hospital

Email: info@benthamscience.net

Yang Lu

Department of Pharmacy, Navy Anqing Hospital

Email: info@benthamscience.net

Wanzhi Yang

Department of Pharmacy,, Anqing First People's Hospital of Anhui Medical University

Email: info@benthamscience.net

Jinhong Xu

Department of Pharmacy, Navy Anqing Hospital

Email: info@benthamscience.net

Mingxing Zhu

Department of Pharmacy, Navy Anqing Hospital

Email: info@benthamscience.net

Yong Huang

Department of Pharmacy, Navy Anqing Hospital

Email: info@benthamscience.net

Fang Bao

Department of Pharmacy, Navy Anqing Hospital

Email: info@benthamscience.net

Shengqi Zheng

Department of Pharmacy, Navy Anqing Hospital

Author for correspondence.
Email: info@benthamscience.net

Yongxia Li

Department of Pharmacy, Navy Anqing Hospital

Author for correspondence.
Email: info@benthamscience.net

References

  1. Magnuson, W.J.; Yeung, J.T.; Guillod, P.D.; Gettinger, S.N.; Yu, J.B.; Chiang, V.L. Impact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastases. Int. J. Radiat. Oncol. Biol. Phys., 2016, 95(2), 673-679. doi: 10.1016/j.ijrobp.2016.01.037 PMID: 27034176
  2. Suwinski, R.; Giglok, M.; Galwas-Kliber, K.; Idasiak, A.; Jochymek, B.; Deja, R.; Maslyk, B.; Mrochem-Kwarciak, J.; Butkiewicz, D. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer. BMC Cancer, 2019, 19(1), 427. doi: 10.1186/s12885-019-5617-1 PMID: 31068179
  3. Fan, T.W.M.; Zhang, X.; Wang, C.; Yang, Y.; Kang, W.Y.; Arnold, S.; Higashi, R.M.; Liu, J.; Lane, A.N. Exosomal lipids for classifying early and late stage non-small cell lung cancer. Anal. Chim. Acta, 2018, 1037, 256-264. doi: 10.1016/j.aca.2018.02.051 PMID: 30292300
  4. Greenberg, A.K.; Lee, M.S. Biomarkers for lung cancer: Clinical uses. Curr. Opin. Pulm. Med., 2007, 13(4), 249-255. doi: 10.1097/MCP.0b013e32819f8f06 PMID: 17534168
  5. Hayat, M.J.; Howlader, N.; Reichman, M.E.; Edwards, B.K. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology and end results (SEER) program. Oncologist, 2007, 12(1), 20-37. doi: 10.1634/theoncologist.12-1-20 PMID: 17227898
  6. Griesinger, F.; Korol, E.E.; Kayaniyil, S.; Varol, N.; Ebner, T.; Goring, S.M. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer, 2019, 135, 196-204. doi: 10.1016/j.lungcan.2019.07.010 PMID: 31446995
  7. de Castria, T.B.; da Silva, E.M.K.; Gois, A.F.T.; Riera, R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Libr., 2013, (8), CD009256. doi: 10.1002/14651858.CD009256.pub2 PMID: 23949842
  8. Wang, S.; Wu, X.; Tan, M.; Gong, J.; Tan, W.; Bian, B.; Chen, M.; Wang, Y. Fighting fire with fire: Poisonous Chinese herbal medicine for cancer therapy. J. Ethnopharmacol., 2012, 140(1), 33-45. doi: 10.1016/j.jep.2011.12.041 PMID: 22265747
  9. Zhong, Z.; Yu, H.; Wang, S.; Wang, Y.; Cui, L. Anti-cancer effects of Rhizoma Curcumae against doxorubicin-resistant breast cancer cells. Chin. Med., 2018, 13(1), 44. doi: 10.1186/s13020-018-0203-z PMID: 30181769
  10. Sang, W.; Zhong, Z.; Linghu, K.; Xiong, W.; Tse, A.K.W.; Cheang, W.S.; Yu, H.; Wang, Y. Siegesbeckia pubescens Makino inhibits Pam3CSK4-induced inflammation in RAW 264.7 macrophages through suppressing TLR1/TLR2-mediated NF-κB activation. Chin. Med., 2018, 13(1), 37. doi: 10.1186/s13020-018-0193-x PMID: 30002726
  11. Zhong, Z.; Zhang, Q.; Tao, H.; Sang, W.; Cui, L.; Qiang, W.; Cheang, W.S.; Hu, Y.; Yu, H.; Wang, Y. Anti-inflammatory activities of Sigesbeckia glabrescens Makino: Combined in vitro and in silico investigations. Chin. Med., 2019, 14(1), 35. doi: 10.1186/s13020-019-0260-y PMID: 31572487
  12. Liu, Y.; Wang, X.; Zeng, S.; Zhang, X.; Zhao, J.; Zhang, X.; Chen, X.; Yang, W.; Yang, Y.; Dong, Z.; Zhu, J.; Xu, X.; Tian, F. The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma. J. Exp. Clin. Cancer Res., 2018, 37(1), 303. doi: 10.1186/s13046-018-0959-0 PMID: 30518397
  13. Liu, D.; You, M.; Xu, Y.; Li, F.; Zhang, D.; Li, X.; Hou, Y. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer. Int. Immunopharmacol., 2016, 39, 265-272. doi: 10.1016/j.intimp.2016.07.035 PMID: 27497194
  14. Samarghandian, S.; Azimi-Nezhad, M.; Farkhondeh, T.; Samini, F. Anti-oxidative effects of curcumin on immobilization-induced oxidative stress in rat brain, liver and kidney. Biomed. Pharmacother., 2017, 87, 223-229. doi: 10.1016/j.biopha.2016.12.105 PMID: 28061405
  15. Chen, P.; Huang, H.P.; Wang, Y.; Jin, J.; Long, W.G.; Chen, K.; Zhao, X.H.; Chen, C.G.; Li, J. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. J. Exp. Clin. Cancer Res., 2019, 38(1), 254. doi: 10.1186/s13046-019-1234-8 PMID: 31196210
  16. Miller, K.D.; Nogueira, L.; Devasia, T.; Mariotto, A.B.; Yabroff, K.R.; Jemal, A.; Kramer, J.; Siegel, R.L. Cancer treatment and survivorship statistics, 2022. CA Cancer J. Clin., 2022, 72(5), 409-436. doi: 10.3322/caac.21731 PMID: 35736631
  17. Devlin, J.R.; Verschuren, E.W. More than a tumor suppressor: E-Cadherin loss drives lung cancer metastasis. Am. J. Respir. Cell Mol. Biol., 2018, 59(2), 141-142. doi: 10.1165/rcmb.2018-0063ED PMID: 29688752
  18. Rosenblum, A.M.; Chasen, M. Comprehensive metastatic lung cancer care must include palliative care. Curr. Oncol., 2018, 25(3), 192-193. doi: 10.3747/co.25.4104 PMID: 29962835
  19. Altorki, N.K.; Markowitz, G.J.; Gao, D.; Port, J.L.; Saxena, A.; Stiles, B.; McGraw, T.; Mittal, V. The lung microenvironment: An important regulator of tumour growth and metastasis. Nat. Rev. Cancer, 2019, 19(1), 9-31. doi: 10.1038/s41568-018-0081-9 PMID: 30532012
  20. Tandberg, D.J.; Tong, B.C.; Ackerson, B.G.; Kelsey, C.R. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. Cancer, 2018, 124(4), 667-678. doi: 10.1002/cncr.31196 PMID: 29266226
  21. Lalla, R.V.; Brennan, M.T.; Gordon, S.M.; Sonis, S.T.; Rosenthal, D.I.; Keefe, D.M. Oral mucositis due to high-dose chemotherapy and/or head and neck radiation therapy. J. Natl. Cancer Inst. Monogr., 2019, 2019(53), lgz011. PMID: 31425601
  22. Li, T.M.; Yu, Y.H.; Tsai, F.J.; Cheng, C.F.; Wu, Y.C.; Ho, T.J.; Liu, X.; Tsang, H.; Lin, T.H.; Liao, C.C.; Huang, S.M.; Li, J.P.; Lin, J.C.; Lin, C.C.; Liang, W.M.; Lin, Y.J. Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan. J. Ethnopharmacol., 2018, 213, 92-100. doi: 10.1016/j.jep.2017.10.031 PMID: 29100936
  23. Liao, Y.H.; Li, C.I.; Lin, C.C.; Lin, J.G.; Chiang, J.H.; Li, T.C. Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients. J. Cancer Res. Clin. Oncol., 2017, 143(12), 2425-2435. doi: 10.1007/s00432-017-2491-6 PMID: 28803328
  24. Li, Z.; Feiyue, Z.; Gaofeng, L. Traditional Chinese medicine and lung cancer-From theory to practice. Biomed. Pharmacother., 2021, 137, 111381. doi: 10.1016/j.biopha.2021.111381 PMID: 33601147
  25. Wang, Q.; Jiao, L.; Wang, S.; Chen, P.; Bi, L.; Zhou, D.; Yao, J.; Li, J.; Wang, L.; Chen, Z.; Jia, Y.; Zhang, Z.; Shen, W.; Zhu, W.; Xu, J.; Gao, Y.; Xu, L.; Gong, Y. Adjuvant chemotherapy with chinese herbal medicine formulas versus placebo in patients with lung adenocarcinoma after radical surgery: A multicenter, randomized, double-blind, placebo-controlled trial. Biol. Proced. Online, 2020, 22(1), 5. doi: 10.1186/s12575-020-00117-5 PMID: 32140080
  26. Li, H.; Ji, Y.; Zhang, S.; Gao, Z.; Hu, C.; Jiang, R.; Chen, M.; Li, G.; Zhang, X. Kangai injection combined with platinum-based chemotherapy for the treatment of stage III/IV non-small cell lung cancer: A meta-analysis and systematic review of 35 randomized controlled trials. J. Cancer, 2019, 10(21), 5283-5298. doi: 10.7150/jca.31928 PMID: 31602279
  27. Jiang, Y.; Liu, L.S.; Shen, L.P.; Han, Z.F.; Jian, H.; Liu, J.X.; Xu, L.; Li, H.G.; Tian, J.H.; Mao, Z.J. Traditional chinese medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial. Complement. Ther. Med., 2016, 24, 55-62. doi: 10.1016/j.ctim.2015.12.006 PMID: 26860802
  28. Mogi, A.; Kuwano, H. TP53 mutations in nonsmall cell lung cancer. J. Biomed. Biotechnol., 2011, 2011, 1-9. doi: 10.1155/2011/583929 PMID: 21331359
  29. Baumann, M.; Zips, D.; Appold, S. Radiotherapy of lung cancer: Technology meets biology meets multidisciplinarity. Radiother. Oncol., 2009, 91(3), 279-281. doi: 10.1016/j.radonc.2009.05.001 PMID: 19464524
  30. Viktorsson, K.; De Petris, L.; Lewensohn, R. The role of p53 in treatment responses of lung cancer. Biochem. Biophys. Res. Commun., 2005, 331(3), 868-880. doi: 10.1016/j.bbrc.2005.03.192 PMID: 15865943
  31. Steels, E.; Paesmans, M.; Berghmans, T.; Branle, F.; Lemaitre, F.; Mascaux, C.; Meert, A.P.; Vallot, F.; Lafitte, J.J.; Sculier, J.P. Role of p53 as a prognostic factor for survival in lung cancer: A systematic review of the literature with a meta-analysis. Eur. Respir. J., 2001, 18(4), 705-719. doi: 10.1183/09031936.01.00062201 PMID: 11716177
  32. Zheng, Q.; Dong, H.; Mo, J.; Zhang, Y.; Huang, J.; Ouyang, S.; Shi, S.; Zhu, K.; Qu, X.; Hu, W.; Liu, P.; Wang, Y.; Zhang, X. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics, 2021, 11(2), 824-840. doi: 10.7150/thno.49600 PMID: 33391507
  33. Harada, D.; Takigawa, N.; Kiura, K. The role of STAT3 in non-small cell lung cancer. Cancers, 2014, 6(2), 708-722. doi: 10.3390/cancers6020708 PMID: 24675568
  34. Yue, P.; Turkson, J. Targeting STAT3 in cancer: How successful are we? Expert Opin. Investig. Drugs, 2009, 18(1), 45-56. doi: 10.1517/13543780802565791 PMID: 19053881
  35. Huang, Q.; Zhong, Y.; Dong, H.; Zheng, Q.; Shi, S.; Zhu, K.; Qu, X.; Hu, W.; Zhang, X.; Wang, Y. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go? Eur. J. Med. Chem., 2020, 187, 111922. doi: 10.1016/j.ejmech.2019.111922 PMID: 31810784
  36. Furtek, S.L.; Backos, D.S.; Matheson, C.J.; Reigan, P. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem. Biol., 2016, 11(2), 308-318. doi: 10.1021/acschembio.5b00945 PMID: 26730496
  37. Wingelhofer, B.; Neubauer, H.A.; Valent, P.; Han, X.; Constantinescu, S.N.; Gunning, P.T.; Müller, M.; Moriggl, R. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia, 2018, 32(8), 1713-1726. doi: 10.1038/s41375-018-0117-x PMID: 29728695
  38. Fan, J.; Ren, D.; Wang, J.; Liu, X.; Zhang, H.; Wu, M.; Yang, G. Bruceine D induces lung cancer cell apoptosis and autophagy via the ROS/MAPK signaling pathway in vitro and in vivo. Cell Death Dis., 2020, 11(2), 126. doi: 10.1038/s41419-020-2317-3 PMID: 32071301

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers